Atossa Therapeutics’ (ATOS) “Buy” Rating Reiterated at HC Wainwright

HC Wainwright reissued their buy rating on shares of Atossa Therapeutics (NASDAQ:ATOS) in a research report sent to investors on Friday morning, Benzinga reports. The firm currently has a $6.00 target price on the stock.

A number of other research firms also recently weighed in on ATOS. Cantor Fitzgerald reaffirmed an overweight rating on shares of Atossa Therapeutics in a report on Thursday, June 20th. Ascendiant Capital Markets boosted their target price on shares of Atossa Therapeutics from $6.00 to $6.25 and gave the company a buy rating in a research note on Thursday, June 6th. Finally, StockNews.com upgraded shares of Atossa Therapeutics from a sell rating to a hold rating in a research note on Tuesday, May 14th.

Atossa Therapeutics Stock Up 4.4 %

ATOS stock opened at $1.19 on Friday. The business’s 50-day simple moving average is $1.39 and its 200 day simple moving average is $1.23. The company has a market cap of $149.65 million, a PE ratio of -4.96 and a beta of 1.19. Atossa Therapeutics has a twelve month low of $0.62 and a twelve month high of $2.31.

Atossa Therapeutics (NASDAQ:ATOS) last issued its earnings results on Monday, May 13th. The company reported ($0.05) EPS for the quarter, beating analysts’ consensus estimates of ($0.07) by $0.02. On average, equities research analysts anticipate that Atossa Therapeutics will post -0.23 EPS for the current year.

Insiders Place Their Bets

In other Atossa Therapeutics news, Director Jonathan Finn bought 25,000 shares of Atossa Therapeutics stock in a transaction dated Wednesday, April 10th. The shares were bought at an average price of $1.77 per share, with a total value of $44,250.00. Following the purchase, the director now owns 25,000 shares of the company’s stock, valued at $44,250. The transaction was disclosed in a document filed with the SEC, which is available at this link. Company insiders own 7.60% of the company’s stock.

Institutional Investors Weigh In On Atossa Therapeutics

Hedge funds have recently modified their holdings of the business. PFG Investments LLC bought a new stake in shares of Atossa Therapeutics in the first quarter valued at about $43,000. Cetera Advisors LLC bought a new stake in shares of Atossa Therapeutics in the first quarter valued at about $72,000. Virtu Financial LLC bought a new position in Atossa Therapeutics during the 1st quarter worth $151,000. Connor Clark & Lunn Investment Management Ltd. bought a new stake in shares of Atossa Therapeutics during the 3rd quarter valued at $98,000. Finally, Vanguard Group Inc. lifted its stake in Atossa Therapeutics by 1.4% during the first quarter. Vanguard Group Inc. now owns 5,753,993 shares of the company’s stock worth $10,357,000 after purchasing an additional 78,269 shares during the last quarter. Institutional investors and hedge funds own 12.74% of the company’s stock.

About Atossa Therapeutics

Atossa Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops medicines in the areas of unmet medical need in oncology for women breast cancer and other conditions in the United States. The company's lead drug candidate is oral (Z)-endoxifen, an active metabolite of tamoxifen, which is in Phase II clinical trials to treat and prevent breast cancer.